Idexx Labs — Financial Results
Revenue Grew 10.4% to $4.3 Billion, Driven Almost Entirely by Organic Growth
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenue | $4.30B | $3.90B | +10.4% |
| Organic Revenue Growth | — | — | +9.6% |
| Currency Impact | — | — | +0.8% |
IDEXX grew revenue by $406 million in 2025, with nearly all of that coming from genuine business growth rather than acquisitions or currency tailwinds. The Companion Animal Group (CAG), which accounts for the vast majority of revenue, grew 9.8% organically, supported by higher testing volumes and price increases. International revenue grew faster (13.7% reported) than the U.S. (8.7%), with currency adding a modest 2.3% boost internationally.
Operating Profit Jumped 20.5%, with Margins Expanding Meaningfully
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Gross Margin | 61.8% | 61.0% | +80 bps |
| Operating Income | $1.36B | $1.13B | +20.5% |
| Operating Margin | 31.6% | 29.0% | +260 bps |
Profitability improved faster than revenue, a positive sign. Gross margin (the percentage of revenue left after direct production costs) expanded because high-margin recurring diagnostic products grew faster than lower-margin instrument sales. Operating margin also benefited from a one-time tailwind: a $61.5 million litigation expense booked in 2024 did not repeat in 2025, and IDEXX actually reversed about $9 million of related accruals in early 2025.
Recurring Diagnostics Are the Engine — But Rapid Assay Tests Are Slipping
| Category | 2025 Revenue | 2024 Revenue | Organic Growth |
|---|---|---|---|
| IDEXX VetLab Consumables | $1.497B | $1.303B | +13.7% |
| Reference Lab Services | $1.424B | $1.336B | +5.9% |
| Rapid Assay Products | $349M | $360M | -3.3% |
Recurring diagnostic revenue — the highly profitable, repeat-purchase business — now makes up 79% of consolidated revenue. Consumables surged 13.7% organically, driven by a 12% expansion in the installed base of premium instruments. However, rapid assay (quick in-clinic test kits) revenue fell 3.3% organically, as customers shifted pancreatic lipase testing onto the Catalyst instrument platform instead.
New inVue Dx Analyzer Drove a 51.8% Surge in Instrument Sales
Instrument revenue jumped from $132 million to $200 million, almost entirely due to the newly launched IDEXX inVue Dx Analyzer, a cytology and cell morphology instrument. The installed base went from zero to 6,000 units in its first full year. This matters beyond the immediate revenue: each placed instrument creates a multi-year stream of high-margin consumable purchases, so today's placements underpin future recurring revenue growth.
Vet Clinic Visit Declines Are a Genuine Headwind to Watch
U.S. same-store clinical visits at veterinary practices fell approximately 2% in 2025, due to a combination of practice staffing constraints and broader macroeconomic pressure on consumer spending. IDEXX's diagnostics revenue per practice still grew about 6% on a same-store basis — meaning vets are testing more per visit — but the company explicitly expects similar visit declines to continue into 2026. This is a sector-wide constraint that caps how fast the underlying market can grow.
Cash Generation Was Strong, but Capital Was Heavily Deployed in Buybacks
| Metric | 2025 | 2024 |
|---|---|---|
| Operating Cash Flow | $1.18B | $929M |
| Cash & Equivalents (year-end) | $180M | $288M |
| Share Repurchases | Significantly higher | — |
Operating cash flow rose 27% to $1.18 billion, a strong result. However, cash on hand fell by $108 million because IDEXX aggressively returned capital to shareholders through share buybacks — spending roughly $380 million more on repurchases than the prior year — and repaid $178 million in maturing debt. The company's net debt to Adjusted EBITDA ratio (a measure of how leveraged the business is relative to its earnings) stood at a very conservative 0.43x, leaving ample financial flexibility.